The mechanism of increased serum creatinine after administration of pyrimethamine and dapsone was evaluated for six healthy volunteers. Serum parameters, urine sediment, and clearances of creatinine, inulin, and para-aminohippurate were assessed prior to and 28 h after the ingestion of a single, combined dose of 100 mg of pyrimethamine and 200 mg of dapsone. In a second series, the same renal function tests were performed for nine human immunodeficiency virus-infected men before and after 1 month of prophylactic treatment with a weekly dose of 75 mg of pyrimethamine and 200 mg of dapsone to evaluate sustained effects on renal function. Serum creatinine increased within 28 h from 81 14 to 102 + 16 ,umol/liter (P = 0.002) in the healthy volunteers. Blood urea nitrogen, 132-microglobulin, and urine remained normal. Creatinine clearance decreased from 125 + 27 to 91 ± 26 ml/min (P < 0.02) without changes in inulin clearance. The effect was reversible within 21 days and attributable to pyrimethamine, as determined by administration of each drug alone. The sustained effect of four doses of pyrimethamine and dapsone in human immunodeficiency virus-infected patients consisted of an analogous rise in serum creatinine from 69 17 to 87 + 32 ,umol/liter (P < 0.05). Both creatinine and inulin clearances, however, were unchanged, representing a new equilibrium between creatinine production and elimination at a higher level in serum. Pyrimethamine, thus, may reversibly inhibit renal tubular secretion of creatinine without affecting the glomerular filtration rate. This physiologic effect in pyrimethamine-treated patients must be differentiated from possible organ-related nephropathies.
The mechanism of increased serum creatinine after administration of pyrimethamine and dapsone was evaluated for six healthy volunteers. Serum parameters, urine sediment, and clearances of creatinine, inulin, and para-aminohippurate were assessed prior to and 28 h after the ingestion of a single, combined dose of 100 mg of pyrimethamine and 200 mg of dapsone. In a second series, the same renal function tests were performed for nine human immunodeficiency virus-infected men before and after 1 month of prophylactic treatment with a weekly dose of 75 mg of pyrimethamine and 200 mg of dapsone to evaluate sustained effects on renal function. Serum creatinine increased within 28 h from 81 14 to 102 + 16 ,umol/liter (P = 0.002) in the healthy volunteers. Blood urea nitrogen, 132-microglobulin, and urine remained normal. Creatinine clearance decreased from 125 + 27 to 91 ± 26 ml/min (P < 0.02) without changes in inulin clearance. The effect was reversible within 21 days and attributable to pyrimethamine, as determined by administration of each drug alone. The sustained effect of four doses of pyrimethamine and dapsone in human immunodeficiency virus-infected patients consisted of an analogous rise in serum creatinine from 69 17 to 87 + 32 ,umol/liter (P < 0.05). Both creatinine and inulin clearances, however, were unchanged, representing a new equilibrium between creatinine production and elimination at a higher level in serum. Pyrimethamine, thus, may reversibly inhibit renal tubular secretion of creatinine without affecting the glomerular filtration rate. This physiologic effect in pyrimethamine-treated patients must be differentiated from possible organ-related nephropathies.
Consistent and unexplained rises in serum creatinine in volunteers participating in the assessment of bioavailability and toxicity of a planned prophylactic treatment were observed. This treatment used weekly combined doses of pyrimethamine and dapsone for prophylaxis of human immunodeficiency virus (HIV)-associated Pneumocystis cannii pneumonia and cerebral toxoplasmosis (19) . Both drugs have only rarely been associated with renal side effects and do not belong to groups of typically nephrotoxic agents (10, 20) . Reduction in glomerular filtration rate can occur as a consequence of a drug-induced nephropathy, including acute tubular necrosis, interstitial nephritis, and intratubular obstruction (10, 20) . On the other hand, certain drugs, such as cimetidine, trimethoprim, and probenecid, have been shown to reduce tubular secretion of creatinine without causing a reduction in glomerular filtration rate (5, 8, 9, 18, 24) . In addition to glomerular filtration, creatinine is also secreted by renal tubules through both the organic anion and the organic cation pathways (15) . The tubular secretion accounts for 5 to 40% of the total amount of excreted creatinine in individuals with normal renal function (4, 11, 12, 14, 22) and can be competitively inhibited by drugs with a similar, aromatic structure (8, 23 (Fig. 1) . Thereafter, serum creatinine fell continuously from day 6 to day 21 after drug intake, normalizing at 104 20 ,umol/liter on day 21. The highest individual value observed was 150 ,umol/liter on day 1.
To determine which drug was responsible for the observed decrease in creatinine clearance, the volunteers were rechallenged with single doses of 200 mg of dapsone and then 100 mg of pyrimethamine, with each dose administered after a drug-free interval exceeding the fivefold half-life time of the drug ingested previously. A 19% increase in serum creatinine occurred after the administration of pyrimethamine, corresponding in magnitude to the rise observed after the administration of pyrimethamine and dapsone together. A single dose of dapsone, however, did not cause any change in serum creatinine (Table 3 ). This part of the study, thus, determined pyrimethamine to be the substance responsible for the rise in serum creatinine.
Sustained effects in patients. Following the administration of four weekly doses of 75 mg of pyrimethamine and 200 mg of dapsone as prophylaxis against P. cannii pneumonia and cerebral toxoplasmosis, serum values of creatinine and renal function tests for nine HIV-infected patients were compared with their pretreatment values. Serum creatinine, measured by colorimetry, increased from 69 ± 17 to 87 ± 32 pumol/liter (P < 0.05). Both creatinine and inulin clearances showed inconsistent courses resulting in marginal, nonsignificant decreases. Renal plasma flow, renal vascular resistance, and mean arterial blood pressure remained unchanged (Table 4) . Results of urine analyses remained normal at all times.
DISCUSSION
Pyrimethamine has not been associated with any typical renal side effects (10, 20) , even though it has been in clinical use for many years. Our study demonstrates for the first time that moderate but consistent rises in serum creatinine occurred after the administration of a single dose of 100 mg of pyrimethamine in persons without any known kidney disease. The acute effects of a combined dose of pyrimethamine and dapsone consisted of a rise in serum creatinine and a fall in creatinine clearance, without changing inulin clearance. A rise in serum creatinine of the same magnitude occurred after pyrimethamine alone but not after dapsone alone. These results confirm that pyrimethamine caused a selective alteration of the renal handling of creatinine without affecting the glomerular filtration rate. Pyrimethamine thus may have selectively blocked the renal tubular secretion of creatinine, which accounts for 5 to 40% of the total amount of excreted creatinine in healthy persons (4, 11, 12, 14, 22) , but can increase to well over 40 to 50% in patients with renal disease (2, 14, 23, 24) . The same mechanism for rises in serum creatinine was shown previously for trimethoprim (4, 5) , cimetidine (8, 9, 24) , and probenecid (18) . Since both pyrimethamine and trimethoprim have similar 2,4-diaminopyrimidine chemical structures (27) , the analogous effect on renal function is not surprising, but it has never been described before.
Despite an acute drop (27.5%) in creatinine clearance, the rise in serum creatinine was only mild to moderate in our healthy volunteers, reaching a peak at 150 ,umol/liter (normal level, < 115 ,umol/liter) in one person and returning to normal within 3 weeks (Fig. 1) . Considering the half-life time of 83 + 14 h for pyrimethamine (3), the rate of normalization was only slightly slower than the serum elimination of pyrimethamine itself. Trimethoprim-induced inhibition of creatinine secretion returns to normal within 7 days (4), reflecting its shorter elimination time (11 ± 1.4 h) (3). The inhibition of creatinine secretion is thus competitive, revers- ible, and independent of the causing drug, representing an alteration of a physiologic mechanism. We, like other authors (13), are not aware of any established evidence suggesting that this effect is deleterious. The evaluation of renal parameters for patients taking 75 mg of pyrimethamine and 200 mg of dapsone once weekly determined the sustained effects after the intake of four combined doses. The 26.7% increase in serum creatinine above the baseline, which was of the same magnitude as the immediate effect of a single dose in volunteers, suggests that tubular secretion was already blocked after the first dose and that no further accumulation occurred during repeated ingestions. The comparison of creatinine clearances before and after 1 month of treatment revealed no change despite a significant increase in serum creatinine. A new steady state with equilibrium between creatinine production and elimination had obviously developed at this time, enabling the kidneys to counterbalance the inhibited creatinine secretion by a relatively increased glomerular filtration from a new, elevated level in plasma (13) . The initially observed decrease in renal plasma flow was paralleled by an increase in renal vascular resistance, suggesting an acute effect of pyrimethamine-dapsone on renal vasculature causing a transient vasoconstriction. The mechanism of this phenomenon is unknown; the effect, however, was not sustained after 1 month.
Although the rate and severity of adverse effects are generally increased in HIV-infected patients (25) , the increase in serum creatinine did not differ between our healthy volunteers and patients with HIV infection, illustrating that the inhibition of creatinine secretion is a physiologic effect. HIV-infected patients are frequently confronted with many different drug treatments, however, and additional drug interactions might, therefore, occur. Furthermore, only limited data on the clinical consequences of inhibited tubular excretion of exogenous substances is available, although many drugs are transported through the tubular organic anion or cation pathway (15) .
The use of pyrimethamine with HIV-infected patients for both prophylaxis and treatment is increasing. The knowledge of this mechanism is, therefore, important and should be considered especially when other potentially nephrotoxic drugs are used. Every increase in serum creatinine must lead to careful consideration of other causes of nephropathy, whether they are drug induced or disease associated (10, 20) . Although the cooccurrence is rare, HIV infection has been shown to coincide with different glomerular and extraglomerular nephropathies (6, 21) .
The use of pyrimethamine in the treatment of malaria could also result in slight-to-moderate increases in serum creatinine. In contrast, acute renal failure as a possible complication of malaria causes real decreases in the glomerular filtration rate (1, 26) and can be distinguished by additional laboratory parameters.
In conclusion, serum creatinine and urine should be regularly monitored for patients treated with pyrimethamine to allow early evaluation of a possible increase in serum creatinine by differentiating between functional, physiologic changes and true impairment of renal function.
